Search Results - sars-cov-2

17 Results Sort By:
­HIGH THROUGHPUT METHOD FOR SCREENING LIPID NANOPARTICLE EFFICACY AND CYTOTOXICITY
­HIGH THROUGHPUT METHOD FOR SCREENING LIPID NANOPARTICLE EFFICACY AND CYTOTOXICITY Researchers at Berkeley have developed synthetic cell membranes that are optimized for screening the toxicity and efficacy of lipid nanoparticle formulations in vitro, in a high throughput format. Lipid nanoparticles (LNPs) represent a highly effective and efficient...
Published: 4/22/2024   |   Inventor(s): Markita Landry, Alison Lui
Keywords(s): Nanoparticle, SARS-CoV-2, Vaccine
Category(s): Technology Classifications > Biology
Biomaterial-Based Vaccine Booster to Enhance Long-Term Immunity (UCLA Case No. 2021-170)
UCLA researchers have developed injectable, cell-free, and biomaterial-based microparticles that can engage with tissue resident immune cells and enhance long-term immunity. It is the first biomaterial-based, targeted approach to induce T memory stem cells (TMSCs) in vivo. The approach was demonstrated for SARS-CoV-2 but can be used for any vaccine....
Published: 7/17/2025   |   Inventor(s): Mohammad Mahdi Hasani Sadrabadi, Song Li, Manish Butte
Keywords(s): aAPCs, Aging, artificial presenting cells, cytokines, elderly, immunosenescence, microparticles, platform technology, SARS-CoV-2, T memory stem cells, TMSCs, Vaccines
Category(s): Therapeutics > Infectious Diseases, Therapeutics > Oncology
Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein
Abstract: The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. Almost all the neutralizing antibodies targeting SARS-CoV-2 that are in development recognize the receptor binding domain (RBD) on the spike...
Published: 5/14/2025   |   Inventor(s): Mitchell Ho, Zhijian Duan, Jesse Buffington
Keywords(s): : COVID-19, ANTIBODY, Camel Nanobody, CORONAVIRUS, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, Shark Nanobody, therapeutic, Vaccine
Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease
Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response
The development of an effective HIV vaccine has been ongoing. HIV sequence diversity and immunodominance are major obstacles in the design of an effective vaccine. Researchers at the National Cancer Institute (NCI) developed a novel vaccine strategy combining both DNA and mRNA vaccination to induce an effective immune response. This combination strategy...
Published: 4/22/2025   |   Inventor(s): Barbara Felber, George Pavlakis
Keywords(s): CANCER VACCINE, DNA vaccine, ENV, Felber, GAG, HIV, Infectious Disease, Nci, Pavlakis, RNA Vaccine, SARS-CoV-2, Vaccine
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Vaccines, TherapeuticArea > Infectious Disease
Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method
Abstract: DNA or RNA-based diagnostic tests for infectious diseases are critical in modern medicine. The current gold standard for COVID-19 detection is testing SARS-CoV-2 viral RNA by quantitative reverse transcription Polymerase Chain Reaction (RT-qPCR). This method involves patient sample collection with a nasopharyngeal swab, storage of the swab...
Published: 5/15/2025   |   Inventor(s): Bin Guan, Robert Hufnagel
Keywords(s): Biomarker, Chelating Resin, Chelex Resin, COVID, COVID-19, DNA/RNA diagnostic test, Extraction-free Detection, Infectious Diseases, SARS-CoV-2, virus
Category(s): TherapeuticArea > Oncology, Application > Diagnostics, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing
Therapeutics Against Pathogenic Coronaviruses
Abstract: The COVID-19 pandemic is a worldwide public health crisis with over 440 million confirmed cases and 6.0 million deaths as of March 2022. COVID-19 is caused by a novel coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). While there are several vaccines available for COVID-19, there are few therapeutics available...
Published: 4/22/2025   |   Inventor(s): Melvin DePamphilis, Matthew Frieman, Arup Chakraborty
Keywords(s): CORONAVIRUS, COVID-19, Depamphilis, Eunice Kennedy Shriver National Institute of Child Health an, Infectious Diseases, MER-CoV, NICHD, PIKfyve Phosphatidyl Linositol Kinase Inhibitors, SARS-CoV, SARS-CoV-2, virus
Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease
Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron
Abstract: Since its emergence in 2019, COVID-19 infected over 600 million people and over 6 million people have died from the disease. COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Neutralizing antibodies have been developed to bind to the receptor binding domain (RBD) on the spike (S) protein. Blocking the interaction of the RBD...
Published: 4/22/2025   |   Inventor(s): Mitchell Ho, Jessica Hong, Jesse Buffington, Zhijian Duan
Keywords(s): ANTIBODY, Camel Nanobody, CORONAVIRUS, COVID-19, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, therapeutic, Vaccine
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, Application > Therapeutics, Collaboration Sought > Licensing
Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19
Abstract: The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. SARS-COV-2 infects hosts via its spike (S) protein. The S protein contains the receptor binding domain (RBD) that binds to the angiotensin converting...
Published: 5/14/2025   |   Inventor(s): Mitchell Ho, Jessica Hong
Keywords(s): ANTIBODY, antigen-binding fragment, CORONAVIRUS, COVID-19, HO, NANOBODY, respiratory INFECTION, S Protein, SARS-CoV-2, spike protein
Category(s): TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics
NRF2 Agonist as Therapeutic Modality to Increase Antiviral Efficacy of Existing Antivirals Against Coronavirus Infections (UCLA Case No. 2022-325)
UCLA researchers in the School of Medicine’s department of Infectious Disease have identified a novel therapeutic approach that can supplement existing FDA approved treatments for SARS-CoV2-2 infections to provide robust treatments against morbidity. BACKGROUND: The World Health Organization reports that as of June 2023, there have been over...
Published: 7/17/2025   |   Inventor(s): Theodoros Kelesidis
Keywords(s): Coronavirus, COVID-19, Paxlovid, SARS-CoV-2, Viral Medication
Category(s): Therapeutics > Infectious Diseases
DEVELOPMENT AND VALIDATION OF A 2-GENE HOST-VIRAL TRANSCRIPTOMIC CLASSIFIER FOR ENHANCED COVID-19 DIAGNOSIS
DEVELOPMENT AND VALIDATION OF A 2-GENE HOST-VIRAL TRANSCRIPTOMIC CLASSIFIER FOR ENHANCED COVID-19 DIAGNOSIS Researchers at UCSF and CZ Biohub SF have developed a two gene host signature that detects COVID infection regardless of the causative viral variant. Though COVID-19 has largely transitioned from pandemic to endemic status, viral variants of...
Published: 5/18/2023   |   Inventor(s): Charles (Chaz) Langelier
Keywords(s): Classifier, COVID, Host Determinants, qPCR, SARS-CoV-2, Viral Diagnostics
Category(s): Technology Classifications > Biology
1 2